Inhibrx Biosciences, Inc.
INBRX-106
head and neck squamous cell carcinoma
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for INBRX-106 in head and neck squamous cell carcinoma are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 11h ago
“We plan to announce PFS data from the randomized Phase 2/3 trial in HNSCC in combination with pembrolizumab in the fourth quarter of 2026 at the European Society for Medical Oncology (“ESMO”) 2026 Congress.”